Suppression of de novo sphingolipid biosynthesis mitigates sarcopenia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37118546.
- Also identified by DOI 10.1038/s43587-022-00307-8 and PMC identifier 10148949.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There are no current standard-of-care treatments for sarcopenia, an age-associated decline in muscle mass and strength. A new study shows that genetically or pharmacologically countering the age-associated accumulation of sphingolipids in skeletal muscle can ameliorate sarcopenia in mice. The authors also identify genetic variants linked to sphingolipid biosynthesis that associate with muscle function in aged humans.
Medical subject headings
- Sarcopenia